Abstract: Scalable 3D-printing of ceramics includes dispensing a preceramic polymer at the tip of a moving nozzle into a gel that can reversibly switch between fluid and solid states, and subsequently thermally cross-linking the entire printed part “at-once” while still inside the same gel. The solid gel, including mineral oil and silica nanoparticles, converts to fluid at the tip of the moving nozzle, allows the polymer solution to be dispensed, and quickly returns to a solid state to maintain the geometry of the printed polymer both during printing and the subsequent high temperature (160° C.) cross-linking. The cross-linked part is retrieved from the gel and converted to ceramic by high temperature pyrolysis. This scalable process opens new opportunities for low-cost, high-speed production of complex 3-dimensional ceramic parts, and will be widely used for high temperature and corrosive environment applications, including electronics and sensors, microelectromechanical systems, energy, and structural applications.

Abstract: Described herein are techniques, methods, and systems for producing hydrocarbons from a reservoir and, particularly, from subterranean formations. The disclosed techniques employ oxygenated solvents, such as ketones, to improve or enhance oil or hydrocarbon production from subterranean formations. In some cases, ketones can be used in combination with surfactants to improve or enhance oil or hydrocarbon from subterranean formations.

Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.

Abstract: Disclosed herein are particle-assisted wakefield electron acceleration devices, accelerated electrons generated using said devices, and methods of use thereof.

Abstract: The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: The current disclosure provides methods and compositions related to treating or preventing neutropenic fever (e.g., cancer therapy-induced neutropenic fever) and/or GVHD (e.g., HCT-related and/or neutropenic fever therapy-induced GVHD). In specific cases, it may be determined whether or not the subject is likely to develop or is at risk of developing neutropenic fever and/or GVHD, such as cancer therapy-induced neutropenic fever and/or HCT-related and/or neutropenic fever therapy-induced GVHD, based on the subject's gut microbiome.

Abstract: Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.

Abstract: The current disclosure provides methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to a peptide comprising at least 70% sequence identity to a peptide of one of SEQ ID NOS:1-776. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of one of SEQ ID NOS:1-776. Further aspects relate to pharmaceutical compositions comprising the peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

Abstract: A passive constraint device is disclosed which attaches to a laparoscopic instrument to kinematically constrain the user from over-gripping the instrument and to train the user in proper handling of the instrument. Passive constraint devices include three degrees of freedom adjustment of a palm rest and clamps to the laparoscopic instrument. An active constraint device is disclosed which attaches to a laparoscopic instrument to dynamically constrain a user from over-gripping the instrument and provide resistive feedback to a user to train the user in proper handling of the instrument. Active constraint devices include a finger guard that, in one embodiment, is elastic and, in other embodiments, is solid but connects to finger loops of a laparoscopic instrument via elastic connectors. Methods of use include a method for training surgical residents in the proper handling of laparoscopic instruments using passive and active constraint devices during residency training.

Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

Abstract: A computerized method and system include (a) estimating parameters that quantify rock fabric features (e.g., tortuosity, effective pore size, throat-size distribution) by joint interpretation of electrical resistivity, dielectric permittivity, and NMR measurements, (b) developing a new workflow for permeability assessment that incorporates the quantified rock fabric parameters, and (c) validating the reliability of the new permeability model in core-scale domain using electrical resistivity, dielectric permittivity, NMR, Mercury Injection Capillary Pressure (MICP), and permeability measurements.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of SEQ ID NO: 1 or 2. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of SEQ ID NO:1 or 2. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

Abstract: The current disclosure provides novel therapeutic methods for treating SCLC and other neuroendocrine cancers by evaluating the biomarker SLFN 11. Aspects of the disclosure relate to a method for treating a subject with small cell lung cancer (SCLC) or with a neuroendocrine cancer, the method comprising administering one or more therapeutics to a subject that has had been evaluated for SLFN 11 expression in a biological sample from the subject; wherein the one or more therapeutics comprise lurbinectedin.

Abstract: In some aspects, the present disclosure provides compositions comprising one or more of each of the following nucleic acids: (1) a mRNA; (2) a sgRNA; and (3) a DNA; and a lipid nanoparticle comprising at least one ionizable lipid; wherein the each of the nucleic acids are encapsulated within the lipid nanoparticle, and pharmaceutical compositions thereof. The present disclosure also provides methods employing said compositions and/or pharmaceutical compositions, such as methods of repairing genes, methods of performing homology directed repair on the genome, and methods of treating diseases or disorders.

Abstract: A test artifact for additive manufacturing is provided. The artifact comprises an additively manufactured singular continuous body between 100 cc and 6 cc in bounding box volume and between 50 cc and 3 cc in solid body. The body comprises at least three fiducials positioned for identification of locations in cross-section after sectioning of the artifact and at least three geometries that are unique from each other when exposed in cross section.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: Aspects of the present disclosure relate to methods and compositions for genetic modification of immune cells to generate immune cells that do not secrete TGF-?1. Also disclosed are methods for use of such genetically modified immune cells, including immunotherapeutic methods for the treatment of cancer. Further aspects of the disclosure are directed to human CD8+ cells comprising a genetic modification that prevents the cells from secreting TGF-?1.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.